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OBJECTIVES: To describe therapy with a Betalactam antibiotic
versus dual therapy with a Betalactam and aminoglycoside treat-
ment regimens in ICU patients with Pseudomonas aeruginosa
nosocomial pneumonia and to evaluate treatment outcomes of
the two groups. METHODS: We retrospectively identiﬁed adult
patients admitted to a non-transplant ICU between August 1,
1999 and August 1, 2003 with documented Pseudomonas aerug-
inosa pneumonia. Patients had to receive at least 7 days of
therapy with an anti-pseudomonal antibiotic to be included.
Data collected included patient, clinical, treatment, and outcome
related details. Independent sample t-test, chi-square and multi-
ple regression analysis was used to evaluate the outcomes of the
patients according to antibiotic groups. RESULTS: A total of 389
patients were identiﬁed with Pseudomonas aeruginosa pneumo-
nia. Of these, 208 (53%) were on Betalactam ± ﬂuroquinolones
(Group 1) and 181 (47%) were on Betalactam and aminoglyco-
side ± ﬂuroquinolones (Group 2). The mean age of patients was
63.1 and 55.4 years in Groups 1 & 2 respectively (p < 0.001).
There was no signiﬁcant difference in the distribution of gender
and race between groups. Group 2 patients had more co-mor-
bidities compared to Group 1. The mean length of antibiotic
therapy in Group 1 was 24.77 and Group 2 52. Seventy-nine
days (p < 0.001) and mean ICU length of stay was 27.6 and 55.2
days in Groups 1 & 2 respectively. The mortality in Group 1
was 51 (24.5%) and in Group 2, it was 65 (35.9%) (p = 0.014).
CONCLUSIONS: The mean length of therapy, ICU length of
stay and mortality are signiﬁcantly lower in monotherapy com-
pared to combination antibiotic treatment group.
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OBJECTIVES: To describe the management of CB and COPD
at stages 1 to 3 (SPLF classiﬁcation, 1997) and to assess its cost
in France. METHODS: In total, 409 CB and COPD patients
were enrolled in the Broncheco cohort from November 2000 to
October 2003 by 10 hospital chest physicians (HP), 50 private
chest physicians (PP) and 63 general practitioners (GP). The
cohort was followed for 1 year with data collection every 3
months: socio-demographic data, medical history and disease
management (medication, oxygen, medical visits, medical pro-
cedures, hospitalisations and transportation). Inpatient costs
were evaluated using the French Diagnosis-Related Groups and
outpatient costs using the French nomenclature. Costs were
expressed in 2003 Euro, according to the French societal per-
spective. Non-parametric statistical analysis was performed.
RESULTS: In total, 316 patients were analysed (random drop-
out was tested) with a mean age of 65 years, a history of the
disease of 8 years, 75% were male and 37% were current
smokers. The distribution in stages was: 21.5%, 42.1%, 22.8%
and 13.6% respectively in stages 1, 2a, 2b, and 3. The annual
cost (both medical and non-medical) was 794€, 1936€, 3938€
and 7706€ respectively for stages 1, 2a, 2b and 3 (p < 0.001).
The proportion of outpatient care in total cost decreased when
stage of disease increased (94%, 70%, 63% and 62% respec-
tively) while the proportion of inpatient care increased (6%,
30%, 37%, 38% respectively). For a same stage of disease, the
costs were higher for HP, lower for PP and the lowest for the GP.
High correlations between cost and age, length of disease and
number of exacerbations were observed: 0.21, 0.23 and 0.49
respectively (p < 0.001). CONCLUSIONS: These results showed
that the cost of COPD was considerably greater in patient with
advanced stage of disease. This would suggest the pertinence of
early management of disease.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the antibiotic consumption in Slovakia
during the period 1998–2002. The special interest was paid to
the trend of the macrolides usage and the resistance of Str.pyo-
genes. Antibiotic treatment and the pharmacoeconomic analysis
of tonsillitis treatment was evaluated. METHODS: For the
period 1998–2002, data for the ambulatory and hospital care
were collected following the ATC/DDD classiﬁcation. The results
were expressed in the numbers of the packages, ﬁnance units
(SKK) and Deﬁned Daily Doses per 1000 inhabitants per day
(DID). RESULTS: The collected data showed very high con-
sumption of the antibiotic in Slovakia. Comparing to the pub-
lished international data it was one of the highest consumers of
antibiotics in Europe. The amount of packages used during the
period 1998–2002 has decreasing tendency. Antibiotic usage
expressed in DID showed moderate decrease. Consumption of
macrolides was increasing during the studied period. Usage of
drugs containing erythromycin and roxithromycin showed sig-
niﬁcant decrease. However, the usage of the drugs containing
clarythromycin and azithromycin showed statistically important
increase (p < 0.001). Different therapeutic procedures were clas-
siﬁed by pharmacoeconomical method of the cost-minimization
analysis. CONCLUSIONS: According to the results of this
analysis, the most effective treatment of tonsillitis was phe-
noxymethylpenicillin 15.30 SKK and penamecillin 18.50 SKK.
Usage of these drugs for the treatment is efﬁcient and economi-
cally convenient (p < 0.001). According to the direct cost analy-
sis, 52.2% of costs used for the treatment of tonsillitis was
“wasted”. Wrong antibiotics were chosen in case of 58.5% of
the patients.
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OBJECTIVES: Inpatient treatment of community-acquired
pneumonia (CAP) is generally non-invasive and therefore the
ﬁnancial burden for hospitals is dependent from length-of-stay.
A fast recovery of the patients shows the need of rapid acting
antibiotic treatment, especially under the German DRG-
reimbursement system. This study investigated costs and charges
of patients with CAP from the hospitals’ perspective. The new
gyrase inhibitor moxiﬂoxacin was compared to standard antimi-
crobial therapy of the participating hospitals. METHODS: The
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observational study was conducted prospectively in a parallel
group design. In 22 hospitals, 580 patients were enrolled, 261
patients in the moxiﬂoxacin-(M-)cohort and 319 patients in the
standard-(S-)cohort of other antibiotics. The economic perspec-
tive of a German hospital was applied for the cost measurement.
After conduct of the study, the patient data were grouped into
the relevant German DRG and the course of treatment, costs and
reimbursement of both cohorts were analysed. RESULTS: The
outcome of the patients at the beginning of treatment was com-
parable in both cohorts. The length-of-stay of the patients was
signiﬁcantly shorter in the moxiﬂoxacin cohort for the more
severe DRGs E62A (M-cohort 10.1 days, N = 113; S-cohort 12.2
days, N = 164; p = 0.004) and E62B (M-cohort 9.7 days, N =
112; S-cohort 10.7 days, N = 146; p = 0.041). In the third DRG
E62C no differences were found (M-cohort 10.2 days, N = 36;
S-cohort 9.4 days, N = 9; p = 0.306). Net proﬁt per case for the
hospitals in the DRG E62A was 1931€ and 1683€ for the cohorts
M and S respectively (E62B: M 1365€, S 1296€; E62C: M 802€,
S 791€). CONCLUSIONS: For the treatment of hospitalised
CAP the study demonstrated the economical relevance of fast
recovery secondary to efﬁcacious drug therapy. Under current
reimbursement modalities the treatment with moxiﬂoxacin is
more proﬁtable from the hospitals’ perspective due to a short-
ened length of stay of the patients.
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OBJECTIVES: Since the beginning of 2004, the diagnosis-related-
groups (DRG) are implemented in the reimbursement procedure
for German hospitals representing a signiﬁcant change for the
hospitals economic situation. As an example for non-invasive
treatment procedures in a German hospital, a prospective health
economic study evaluated the treatment costs of community-
acquired pneumonia (CAP) from the hospital’s perspective.
Results of an interim analysis were published in 2003, now the
ﬁnal results of the study are presented. METHODS: Open, non-
randomized prospective observational study from the perspective
of the German hospital administration. In 11 study centres, 319
patients were enrolled. A process-cost-analysis was performed to
determine the costs for the German hospital sector starting from
the admission up to the discharge of the patient. The cost calcu-
lation comprises diagnostic and therapeutic measures, drugs,
hotel costs and nursing. Both personnel costs and material costs
were included. Acquisition of medical devices was not included
into the analysis. RESULTS: The patients enrolled suffered from
moderate to severe stages of CAP with a mean length-of-stay of
11.5 days (peripheral ward: 10.7; ICU 0.8). Mean costs per
patient amounted to 1528€ (SD: 1011€). Most important cost-
driving factors were hotel costs (640€) and nursing (554€). Drug
acquisition cost resulted in 201€, whereas costs for diagnostics
(80€) and therapeutic measures (54€) were comparatively low.
The most often applied drugs were macrolides (37.6% of the
patients), b-lactamase inhibitor-aminopenicillin combinations
(32.3%), and cephalosporins of 2nd (30.4%) and 3rd generation
(28.5%). Thirty-six patients (11.3%) died during the hospital
stay. CONCLUSIONS: In hospitalised CAP, length of stay deter-
mines the costs from the economic perspective of the hospital,
which underlines the importance of a reduction of length of stay
in this indication. The need for rapid and safe antibiotic treat-
ment becomes evident especially under consideration of the DRG
reimbursement system.
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OBJECTIVE: To estimate health care costs for the treatment of
acute exacerbation of chronic bronchitis (AECB) and commu-
nity-acquired pneumonia (CAP) in 4 previously-reported Phase
III multinational comparative trials of telithromycin vs 
amoxicillin-clavulanic acid and clarithromycin in Canada.
METHODS: In each of the 4 studies, patients were followed for
1 month and the primary endpoint was clinical efﬁcacy at the
posttherapy/test of cure (TOC) visit. Each trial prospectively col-
lected data on study indication-related hospitalizations, addi-
tional health care provider visits, and additional antibiotic
therapy. Three trials also collected information on additional lab-
oratory and other tests and procedures. Cost analyses were per-
formed from the perspective of the Ontario Ministry of Health.
RESULTS: A total of 1045 and 853 patients in the 4 trials were
randomized to receive telithromycin or a comparator, respec-
tively. At baseline, the patient groups were similar with respect
to demographic and clinical characteristics. The clinical efﬁcacy
of telithromycin and the comparators was similar in each study.
Compared to patients randomized to comparator, those ran-
domized to telithromycin were less likely to require AECB- and
CAP-related hospitalization. Total and average costs of care were
approximately 2 to 3 times higher in the comparator groups,
driven by higher hospitalization rates. The ratio of average total
treatment cost per patient in each comparator to that of
telithromycin was as follows: $40/$19 = 2.1 for amoxicillin-
clavulanic acid in AECB; $241/$122 = 1.9 for clarithromycin in
AECB; $198/$109 = 1.8 and $293/$90 = 3.3, for clarithromycin
in CAP. CONCLUSION: Although clinical cure rates for
telithromycin, amoxicillin-clavulanic acid, and clarithromycin
are comparable, health care costs appear to be lower among
patients taking telithromycin, a ﬁnding driven by fewer hospi-
talizations. Since hospitalization accounts for a major propor-
tion of the direct health care costs associated with AECB and
CAP in Canada, the use of telithromycin may signiﬁcantly reduce
the total costs of care for these respiratory conditions.
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OBJECTIVES: COPD is a chronic disease that causes disability
and increases with age. The aim was to assess the quality of life
of COPD patient treated in Primary Assistance in Spain.
